ABSTRACT
El pioderma gangrenoso (PG), es una dermatosis neutrofílica, cutáneo-ulcerativa, no infecciosa, que ocurre hasta en un 2% de los pacientes con enfermedad de Crohn (EC). Su aparición suele ser independiente del curso clínico de la EC. Las terapias más utilizadas han sido los corticoides sistémicos, la ciclosporina y la terapia biológica, los cuales han mostrado buenos resultados. El Metotrexate (MTX) es un fármaco antimetabolito con actividad antiinflamatoriaque se caracteriza por una dosificación semanal, un inicio de acción más rápida, con buen perfil de seguridad relacionado con neoplasias malignas y sobretodo un menor costo. Posee eficacia en la inducción de la remisión en pacientes con EC, sin embargo su eficacia en el manejo de manifestaciones extraintestinales como el PG es incierta. Presentamos el caso de un varón joven que acude a urgencias por diarrea crónica, pérdida de peso, y fiebre acompañado de un nódulo doloroso, eritematoso, situado a nivel pretibial compatible con PG en el contexto de EC. Fue manejado inicialmente con corticoides sistémicos sin mejoría. De tal forma, se inició terapia concomitante con MTX con respuesta clínica y analítica favorable. En conclusión, la terapia concomitante de cortiocoides sistémicos y MTX en pacientes con EC con PG podría suponer un tratamiento alternativo al no contar con disponibilidad de ciclosporina o terapia biológica en nuestro medio.
Pyoderma gangrenosum (PG) is a neutrophilic, cutaneous-ulcerative, non-infectious dermatosis that occurs in up to 2% of patients with Crohn's disease (CD). Its appearance is usually independent of the clinical course of CD. The most used therapies have been systemic corticosteroids, cyclosporine and biological therapy, which have shown good results. Methotrexate (MTX) is an antimetabolite drug with anti-inflammatory activity characterized by a weekly dosage, a faster onset of action, with a good safety profile related to malignant neoplasms and, above all, a lower cost. It is effective in the induction of remission in patients with CD, however its efficacy in the management of extraintestinal manifestations such as PG is uncertain. We present the case of a young man who comes to the emergency room with an history of chronic diarrhea, weight loss, and fever accompanied by a painful, erythematous nodule, located at the lower extremity compatible with PG in the context of CD. It was initially managed with systemic corticosteroids without improvement. Concomitant therapy with MTX was started with a favorable clinical outcome. In conclusion, the concomitant therapy of systemic corticosteroids and MTX in patients with CD with PG could be an alternative treatment in cases where cyclosporine or biological therapy is not available.
Subject(s)
Adult , Humans , Male , Methotrexate/therapeutic use , Pyoderma Gangrenosum/drug therapy , Leg Dermatoses/drug therapy , Antimetabolites/therapeutic use , Remission Induction , Crohn Disease/complications , Pyoderma Gangrenosum/etiology , Leg Dermatoses/etiologyABSTRACT
El objetivo del Consenso Mexicano para el Tratamiento de la Hepatitis C fue el de desarrollar un documento como guía en la práctica clínica con aplicabilidad en México. Se tomó en cuenta la opinión de expertos en el tema con especialidad en: gastroenterología, infectología y hepatología. Se realizó una revisión de la bibliografía en MEDLINE, EMBASE y CENTRAL mediante palabras claves referentes al tratamiento de la hepatitis C. Posteriormente se evaluó la calidad de la evidencia mediante el sistema GRADE y se redactaron enunciados, los cuales fueron sometidos a voto mediante un sistema modificado Delphi, y posteriormente se realizó revisión y corrección de los enunciados por un panel de 34 votantes. Finalmente se clasificó el nivel de acuerdo para cada oración. Esta guía busca dar recomendaciones con énfasis en los nuevos antivirales de acción directa y de esta manera facilitar su uso en la práctica clínica. Cada caso debe ser individualizado según sus comorbilidades y el manejo de estos pacientes siempre debe ser multidisciplinario.
The aim of the Mexican Consensus on the Treatment of Hepatitis C was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitis C treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary.
Subject(s)
Humans , Hepatitis C , Hepatitis C/therapy , Ribavirin/therapeutic use , Hepatitis C/drug therapy , Antimetabolites/therapeutic useABSTRACT
Abstract Purpose: To analyze the effects of allopurinol and of post-conditioning on lung injuries induced by lower-limb ischemia and reperfusion. Methods: Thirty rats were used. They were divided in 5 groups: (1) group A: abdominal aortic dissection only, (2) group B: ischemia and reperfusion, (3) group C: administered allopurinol (100mg/Kg) a few hours before procedure, (4) group D: post-conditioned and (5) group E: administered allopurinol and post-conditioned. With the exception of group A, all groups were submitted to infrarenal aortic ischemia for 2 hours, and reperfusion for 72 hours. After euthanasia, lungs were removed for histological analysis. They were graded under two scores: pulmonary injury (neutrophil infiltration, interstitial edema, vascular congestion, and destruction of lung architecture) and lymphocytic score (neutrophil infiltration, lymphoid aggregate and secondary follicle). Results: On the pulmonary injury score, the degree of injury was smaller than in groups D and E, when compared to group B, p<0.05. Group C did not obtain the same result (p>0,05). On the lymphocytic score, there was no statistic difference among groups, p>0.05. Conclusion: Both post-conditioning and the combination of allopurinol and post-conditioning were effective in remote lung protection induced by lower-limbs I/R. When used in isolation, allopurinol showed no protective effect.
Subject(s)
Animals , Male , Female , Rats , Reperfusion Injury/complications , Allopurinol/therapeutic use , Lung Injury/prevention & control , Ischemic Postconditioning , Rats, Wistar , Disease Models, Animal , Lung Injury/etiology , Antimetabolites/therapeutic useABSTRACT
Crohn´s disease (CD) is an intestinal pathology that may have a torpid and disabling course. One of the purposes of the pharmalogical therapy is to prevent progression of the disease and keep the patient in clinical remission. Thiopurines (azathioprine (AZT)/6-mercaptopurine (6-MP)) correspond to a group of drugs so far recommended in all current consensus for maintaining remission of the disease. Recent publications have questioned its effectiveness as a maintenance treatment. We reviewed the literature to date and the aforementioned publications trying to clarify the current status of the use of AZT/6-MP in CD. We emphasize the importance of thiopurine therapy guided by levels of its metabolites, 6-thioguanines and 6-metilmercaptopurines and usefulness of Allopurinol in selected cases. It is still pending to determine whether thiopurines have the potential to modify the disease at an early stage. Further studies are needed before conclusions can modify our clinical behavior to continue using AZT/6-MP in patients with CD.
La enfermedad de Crohn (EC) es una enfermedad intestinal que puede tener un curso tórpido e invalidan. Uno de los objetivos del tratamiento farmacológico es evitar la progresión de la enfermedad y mantener al paciente en remisión. Las tiopurinas (azatioprina (AZT)/6-mercaptopurina (6-MP) corresponden a un grupo de fármacos hasta ahora recomendados en todos los consensos para mantener la remisión de esta enfermedad. Publicaciones recientes han cuestionado su efectividad como tratamiento de mantención. Revisamos la literatura disponible hasta la fecha y las mencionadas publicaciones, intentando esclarecer el estatus actual del uso de AZT/6-MP en EC. Recalcamos la importancia de realizar la terapia con tiopurinas guiada según los niveles de sus metabolitos 6-tioguaninas y 6-metilmercaptopurinas y la utilidad del uso de alopurinol en casos seleccionados. Conclusión: Está pendiente determinar si las tiopurinas tienen el potencial de modificar la enfermedad tempranamente. Se requieren mayores estudios antes de sacar conclusiones que modifiquen nuestra conducta clínica en lo que respecta a seguir usando AZT/6-MP en pacientes con EC.
Subject(s)
Humans , /therapeutic use , Azathioprine/therapeutic use , Crohn Disease/drug therapy , Immunosuppressive Agents/therapeutic use , Antimetabolites/therapeutic use , Remission InductionABSTRACT
The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients. We retrospectively reviewed patients who were diagnosed to have gout with at least 3 yr of follow up. They were divided into 2 groups; 53 patients with mean serum uric acid level (sUA) or =6 mg/dL. Comorbidities of gout such as hypertension (HTN), type II diabetes mellitus (DM), chronic kidney disease, cardiovascular disease (CVD) and urolithiasis were compared in each group at baseline and at last follow-up visit. Frequency of acute gout attacks were also compared between the groups. During the mean follow up period of 7.6 yr, the yearly rate of acute attack and the new development of HTN, DM, CVD and urolithiasis was lower in the adequately treated group compared to the inadequately treated group. Tight control of uric acid decreases the incidence of acute gout attacks and comorbidities of gout such as HTN, DM, CVD and urolithiasis.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Allopurinol/therapeutic use , Antimetabolites/therapeutic use , Benzbromarone/therapeutic use , Cardiovascular Diseases/epidemiology , Comorbidity , Diabetes Mellitus, Type 2/epidemiology , Enzyme Inhibitors/therapeutic use , Gout/drug therapy , Gout Suppressants/therapeutic use , Hypertension/epidemiology , Renal Insufficiency, Chronic/epidemiology , Retrospective Studies , Thiazoles/therapeutic use , Uric Acid/blood , Uricosuric Agents/therapeutic use , Urolithiasis/epidemiologyABSTRACT
OBJECTIVE: To compare the efficacy of transconjunctival needling revision with 5-fluorouracil versus medical treatment in glaucomatous eyes with uncontrolled intraocular pressure due to encapsulated bleb after trabeculectomy. METHODS: Prospective, randomized, interventional study. A total of 40 eyes in 39 patients with elevated intraocular pressure and encapsulated blebs diagnosed at a maximum five months after primary trabeculectomy with mitomycin C were included. The eyes were randomized to either transconjunctival needling revision with 5- fluorouracil or medical treatment (hypotensive eyedrops). A maximum of two transconjunctival needling revisions per patient was allowed in the needling arm. All patients underwent follow-up for 12 months. Successful treatment was defined as an intraocular pressure ≤ 18 mmHg and a 20% reduction from baseline at the final follow-up. Clinicaltrial.gov: NCT01887223. RESULTS: Mean intraocular pressure at the final 12-month follow-up was lower in the transconjunctival needling revision group compared to the medical treatment group. Similar numbers of eyes reached the criteria for treatment success in both the transconjunctival needling revision group and the medical treatment group. CONCLUSIONS: Despite similar success rates in eyes randomized to transconjunctival needling revision with 5-fluorouracil compared to eyes receiving medical treatment, there was a significantly lower mean intraocular pressure at 12 months after transconjunctival needling revision. .
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Antimetabolites/therapeutic use , Blister/therapy , Conjunctiva/surgery , Fluorouracil/therapeutic use , Glaucoma/surgery , Trabeculectomy/adverse effects , Blister/etiology , Conjunctiva/drug effects , Intraocular Pressure , Needles , Postoperative Complications , Prospective Studies , Statistics, Nonparametric , Time Factors , Treatment OutcomeABSTRACT
Amyloidosis is characterized by a deposition of insoluble fibrils in various organs and tissues. Amyloid deposition, in the gastrointestinal track, provokes a dysfunction of the organ, due to an accumulation of fibrils, and causes a variety of clinical symptoms and endoscopic findings. Primary amyloidosis in the gastrointestinal tract is rarely reported in Korea. We experienced a case of recurrent intestinal bleeding, in a 59-year-old female patient with primary amyloidosis. A colonoscopy revealed the presence of multiple large circular ulcers. In the entire colon, diffuse nodular lesions with edema and bleeding were found. A colonoscopic biopsy established the diagnosis of amyloidosis, to the exclusion of other disease components. We concluded that the patient had localized amyloidosis. Though a definitive therapeutic strategy has not been established for localized gastrointestinal amyloidosis, the patient has been successfully treated with a high-dose of steroids and azathioprine.
Subject(s)
Female , Humans , Middle Aged , Mercaptopurine/analogs & derivatives , Amyloidosis/diagnosis , Antimetabolites/therapeutic use , Colon/pathology , Colonoscopy , Gastrointestinal Hemorrhage , Steroids/therapeutic use , Tomography, X-Ray ComputedABSTRACT
Although the incidence and prevalence rates of IBD in Korea are still lower than Western populations, they have been increasing rapidly during the past decades. Crohn's disease (CD) tends to run in families because it is thought to be related to genetic susceptibility coupled with environmental factors. A large number of monozygotic and dizygotic twin pairs with inflammatory bowel disease have been reported in western countries. The population relative risk in first-degree relatives is considered to be about equal in both Koreans and westerners. To our best knowledge, there is no report in monozygotic twins with CD in Korea. This case report is the first documented occurrence of concordant CD occurring in monozygotic twins in Korea.
Subject(s)
Adolescent , Humans , Male , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Colonoscopy , Crohn Disease/diagnosis , Diseases in Twins/diagnosis , Pedigree , Tomography, X-Ray Computed , Twins, Monozygotic/geneticsABSTRACT
Although the incidence and prevalence rates of IBD in Korea are still lower than Western populations, they have been increasing rapidly during the past decades. Crohn's disease (CD) tends to run in families because it is thought to be related to genetic susceptibility coupled with environmental factors. A large number of monozygotic and dizygotic twin pairs with inflammatory bowel disease have been reported in western countries. The population relative risk in first-degree relatives is considered to be about equal in both Koreans and westerners. To our best knowledge, there is no report in monozygotic twins with CD in Korea. This case report is the first documented occurrence of concordant CD occurring in monozygotic twins in Korea.
Subject(s)
Adolescent , Humans , Male , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Colonoscopy , Crohn Disease/diagnosis , Diseases in Twins/diagnosis , Pedigree , Tomography, X-Ray Computed , Twins, Monozygotic/geneticsABSTRACT
OBJETIVO: O transtorno de pânico é uma condição crônica e recorrente que prejudica a qualidade de vida e o funcionamento psicossocial dos portadores. Embora os medicamentos sejam efetivos na redução dos ataques de pânico, muitos pacientes não respondem adequadamente a essas intervenções. A terapia cognitivo-comportamental fornece um método alternativo eficaz para tratar transtorno de pânico e evitação agorafóbica. O objetivo do estudo é o de descrever o uso de técnicas cognitivo-comportamentais no tratamento do transtorno de pânico. MÉTODO: Revisão narrativa a partir dos bancos de dados do Medline, SciELO e PsycInfo e de livros-texto especializados. RESULTADOS: Foram descritos os fundamentos da terapia cognitivo-comportamental no tratamento do transtorno pânico e revisadas as evidências de eficácia em curto e longo prazos. O uso de medicação concomitante a terapia cognitivo-comportamental foi também discutido. CONCLUSÕES: A terapia cognitivo-comportamental individual ou em grupo é eficaz para pacientes com transtorno de pânico, seja como tratamento de primeira linha ou como um próximo passo para pacientes com resposta parcial a outros tratamentos.
OBJECTIVE: Panic disorder is a chronic and recurrent condition that impairs an individual's psychosocial functioning and quality of life. Despite the efficacy of psychopharmacological treatment in reducing panic attacks, many patients fail to respond adequately to these interventions. Cognitive behavioral therapy provides an alternative and efficacious method for treating panic disorder and agoraphobic avoidance. The objective of the study is to describe the use of cognitive behavioral therapy for panic disorder. METHOD: Narrative review of data collected from Medline, SciELO and PsycInfo and specialized textbooks. RESULTS: We describe the cognitive-behavioral model for the treatment of panic disorder, and review both short and long-term efficacy findings. We also discuss the role of combined treatment (cognitive behavioral therapy and psychopharmacology). CONCLUSIONS: Cognitive behavioral therapy, either individual or in group, can be used as first-line therapy for panic disorder. This treatment modality can also be indicated as a next step for patients failing to respond to other treatments.
Subject(s)
Humans , Cognitive Behavioral Therapy/methods , Panic Disorder/therapy , Agoraphobia/psychology , Agoraphobia/therapy , Antimetabolites/therapeutic use , Cycloserine/therapeutic use , Panic Disorder/etiology , Panic Disorder/psychology , Recurrence , Treatment OutcomeABSTRACT
Urological complications are not uncommon in Crohn's disease (CD). The most common manifestations are renal stones, enterovesical fistulas, and ureteral obstruction, but renal parenchymal disease has rarely been reported. IgA nephropathy, the most common form of primary glomerulonephritis, is usually isolated, but can be sometimes associated with chronic extrarenal disorders such as inflammatory bowel disease. We describe a case of 36 year-old man with CD associated with IgA nephropathy. He was diagnosed as CD 6 years ago and at that time, isolated proteinuria was observed. He presented recurrent proteinuria and elevation of creatinine level while he had been managed well with mesalamine and azathioprine. The renal biopsy was performed and IgA nephropathy (type IV) was diagnosed. Strict blood pressure control with angiotensin converting enzyme inhibitor and calcium channel blocker resulted in clinical improvement and normalization of serum creatinine level.
Subject(s)
Adult , Humans , Male , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Blood Pressure , Calcium Channel Blockers/therapeutic use , Colonoscopy , Crohn Disease/diagnosis , Glomerulonephritis, IGA/complications , Mesalamine/therapeutic use , Proteinuria/diagnosisABSTRACT
No abstract available.
Subject(s)
Humans , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Chronic Disease , Colitis, Ulcerative/diagnosis , Hemoglobins/analysis , Mesalamine/therapeutic use , Recurrence , Risk FactorsABSTRACT
BACKGROUND/AIMS: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with heterogeneous clinical features. Data on the disease course and prognosis of UC patients who have been regularly treated are lacking. We aimed to investigate relapse rates of UC in remission and factors related to relapse. METHODS: We retrospectively analyzed clinical courses of 84 patients (43 males, median age 43 years, ranged 20-73 years) diagnosed as UC at Ajou University Hospital between January 1997 and December 2005 based on clinical, endoscopic and pathologic findings, and who were regularly followed for at least one year after the remission. RESULTS: Study subjects consisted of 32 proctitis (38%), 21 left-sided colitis (25%), and 31 subtotal or total colitis (37%). Of 84 patients, relapse was observed in 52 patients (62%) during the follow-up period (ranged 1-9 years). The relapse rate was 24%, 41%, 51%, 65%, 71%, and 79% at 1 year, 2 years, 3 years, 4 years, 5 years and 6 years, respectively. Among sex, age, hemoglobin, ESR, and the extent of disease on admission, decrease of hemoglobin level was the only independent factor related to relapse (odds ratio=2.67, 95% CI (1.32-5.42), p<0.01). CONCLUSIONS: In Korea, relapse of UC in remission is not rare. Decrease of hemoglobin level is an independent risk factor related to its relapse, while the extent of disease is not.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Chronic Disease , Colitis, Ulcerative/diagnosis , Data Interpretation, Statistical , Follow-Up Studies , Hemoglobins/analysis , Mesalamine/therapeutic use , Odds Ratio , Recurrence , Retrospective Studies , Risk Factors , Time FactorsABSTRACT
Chemotherapy is expected to play an important role in the treatment of pancreatic cancer because most of pancreatic cancers are being discovered at locally advanced or metastatic stages and recurrence rate is high even after the curative resection. Gemcitabine is a key agent for the first-line therapy of advanced pancreatic cancer. It can enhance the quality of life and prolong the survival of patients. Combination of erlotinib or capecitabine with gemcitabine showed a marginal survival benefit over single-agent gemcitabine. If patient's performance state is good, gemcitabine-based platinum combination therapy showed overall survival benefit compared with gemcitabine monothrapy. If the first-line palliative chemotherapy fails, 5-FU, capcitabine, or tegafur with or without combination can be used as the second-line agents. Adjuvant chemotherapy using 5-FU or gemcitabine after curative resection has overall survival benefit. However, neoadjuvant chemotherapy has not been proven to be effective in the treatment of pancreatic cancer.
Subject(s)
Humans , Antimetabolites/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Chemotherapy, Adjuvant , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic useABSTRACT
Radiotherapy has been offered to patients with pancreatic cancer, either in the adjuvant or definitive setting. However, the role of radiotherapy in pancreatic cancer is increasingly doubted, especially after the introduction of gemcitabine to both domains. Although contradictory data exist, combined chemoradiotherapy improves both quantity and quality of life for patients with locally advanced tumors compared with radiotherapy alone or chemotherapy alone. Recently, induction chemotherapy strategy is being evaluated for better selection of patients for optimal benefit from consolidative chemoradiotherapy. Much controversy has been suggested concerning the role of adjuvant radiotherapy, but quality assurance for radiotherapy was not considered in the previously reported studies. Combined chemoradiotherapy in the adjuvant setting is still considered as a viable option. Current phase III randomized on-going studies will provide better answers on the role of radiotherapy in the treatment of pancreatic cancer.
Subject(s)
Humans , Antimetabolites/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Combined Modality Therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/therapeutic use , Pancreatic Neoplasms/drug therapyABSTRACT
INTRODUCTION: The exact mechanism of chronic nonbacterial prostatitis has not been yet elucidated and the outcome with the current management is dismal. In this trial, we studied the effect of allopurinol in the treatment of this disease. MATERIALS AND METHODS: In this randomized double blind controlled trial, a calculated sample size of 56 were grouped into "intervention group" who received allopurinol (100 mg tds for 3 months) with ofloxacin (200 mg tds) for 3 weeks (n = 29) and "control group" who received placebo tablets with ofloxacin (n = 27). PatientsÆ scores based on the National Institute of Health Chronic Prostatitis Symptom Score were recorded before therapy and then every month during the study. A four-glass study was performed before intervention and after 3 months. RESULTS: The 2 groups were similar regarding outcome variables. In the first month of study, a significant but similar improvement in symptom scores was observed in both groups. Microscopic examination of prostate massage and post-massage samples were also similar in both groups. No side effects due to allopurinol were observed in patients. CONCLUSION: We did not find any advantage for allopurinol in the management of chronic prostatitis versus placebo in patients receiving routine antibacterial treatment.
Subject(s)
Adult , Humans , Male , Allopurinol/therapeutic use , Anti-Infective Agents, Urinary/therapeutic use , Antimetabolites/therapeutic use , Ofloxacin/therapeutic use , Prostatitis/drug therapy , Allopurinol/administration & dosage , Anti-Infective Agents, Urinary/administration & dosage , Antimetabolites/administration & dosage , Chronic Disease , Double-Blind Method , Drug Therapy, Combination , Ofloxacin/administration & dosageABSTRACT
Sympathetic Ophthalmia is a rare and blinding ocular complication due to ocular injury. This condition in a male patient aged 25 years, is reported. The role of early recognition and management of this condition to preserve good vision is discussed.
Subject(s)
Adult , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Blindness/prevention & control , Glucocorticoids/therapeutic use , Humans , Male , Ophthalmia, Sympathetic/drug therapy , Ophthalmoscopy , Uvea/injuriesABSTRACT
Cutaneous leishmanasis (CL) may present with unusual clinical variants such as acute paronychial, annular, palmoplantar, zosteriform, erysipeloid, and sporotrichoid. The zosteriform variant has rarely been reported. Unusual lesions may be morphologically attributed to an altered host response or owing to an atypical strain of parasites in these lesions. We report a patient with CL in a multidermatomal pattern on the back and buttock of a man in Khozestan province in the south of Iran. To our knowledge, this is the first reported case of multidermatomal zosteriform CL. It was resistant to conventional treatment but responded well to a combination of meglumine antimoniate, allopurinol, and cryotherapy.
Subject(s)
Allopurinol/therapeutic use , Antimetabolites/therapeutic use , Antiprotozoal Agents/therapeutic use , Chronic Disease , Cryotherapy , Drug Therapy, Combination , Humans , Leishmaniasis, Cutaneous/diagnosis , Male , Meglumine/therapeutic use , Middle Aged , Organometallic Compounds/therapeutic useABSTRACT
Objetivos: Demostrar la utilidad de los anitmetabolitos como coadyuvante del tratamiento quirúrgico de los estrabismo restrictivos adherenciales. Pacientes y métodos: Se presentaron 10 pacientes con diagnóstico de estrabismo restrictivo adherencial, algunos recidivados , a los que luego de la cirugía para liberar las adherencias, se les colocó Mitomicina C (MMC) ó 5-fluoruracilo (5-FU) en el lecho cruento. Resultados: Luego de un seguimiento de entre 6 meses y 1 año, los pacientes no tuvieron recidiva de las adherencias, ni complicaciones post quirúrgicas asociadas a su uso. Conclusiones: El uso de antimetabolitos en el lecho cruento es una técnica simple y eficaz para prevenir nuevas adherencias.
Objectives: To demostrate the efficacy of anitmetabolites used as a coadjuvant of the adhesion restrictive strabismus surgical treatment. Patients and methods: Ten patients are being presented with diagnosis of adhesion restrictive strabismus that underwent surgical removal of the adhesions with the application of antimetabolites (5-FU or MMC depending on the case). Results: After a follow up of between 6 months to a year, none of the patients had recurrence of the adhesions or postoperative complications due to the use of antimetabolites. Conclusions: The application of antimetabolites on the surgical bed is an effective and simple resource to prevent new adhesions.